Print Friendly, PDF & Email

NCT/Study#

NCT04289779 /

GU18-343

A Phase 2 Study Of Cabozantinib In Combination With Atezolizumab As Neoadjuvant Treatment For Muscle-Invasive Bladder Cancer (ABATE)

DISEASE GROUP:
Genito-Urinary
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: